BridgeMD
Tests treatment safety and results for Pancreatic Cancer
Official title A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
ClinicalTrials.gov ID: NCT06758544
What this study is testing
What is Oncolytic virus VRT106?
Oncolytic virus VRT106 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for pancreatic cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of...
- Males and females at 18-75 years of age, inclusive, at the Screening Visit.
- Have a clinical diagnosis of pancreatic cancer.
- An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Expected survival time of≥6 months.
You likely can't join if
- Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
- Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
- Immunocompromised patients.
- Known alcohol or drug dependency.
- Women who are pregnant or breastfeeding.
See the full eligibility criteria
- Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
- Males and females at 18-75 years of age, inclusive, at the Screening Visit.
- Have a clinical diagnosis of pancreatic cancer.
- An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Expected survival time of≥6 months.
- No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.
- Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
- Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
- Immunocompromised patients.
- Known alcohol or drug dependency.
- Women who are pregnant or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.